Smithkline Beecham Corporation

Glaxo Group Limited

Glaxosmithkline LLC

Aaron Bayne Miller

Frank Navas, Iii

Dennis Heyer

Subba Reddy Katamreddy

Jing Fang

William John Zuercher

Terrence Lee Smalley, Jr

Christopher Norbert Johnson

Andrew Kenneth Takle

Steven James Stanway

David Norman Deaton

David Timothy Macpherson

John George Catalano

Giancarlo Trani

Xi Liang

David G Jones

William Joel Hoekstra

Francis Xavier Tavares

Istvan Kaldor

Philip Stewart Turnbull

Curt Dale Haffner

Darryl Lynn McDougald

Antoinette Naylor

John Albert Ray

Jennifer Poole Peckham

David Gene Barrett

Vicente Samano

Adwoa Akwabi-Ameyaw

Jonathan E Britton

Harikrishna Suryakant Patel

Antoinette Wilson

The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.

Indazoles used to treat estrogen receptor beta mediated disorders

The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.

Compounds

The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.

Cycloalkylidene compounds as modulators of estrogen receptor

The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen receptor modulation.

Naphthalene compounds as selective estrogen receptor modulators

The present invention relates to novel compounds of formula (I) with a variety of therapeutic uses, more particularly novel substituted quinoline compounds particularly useful for selective estrogen receptor modulation. 

Substituted quinoline compounds for use as selective estrogen receptor modulator

Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss

Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors

The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXR&#x3b1;, RXR&#x3b2;, or RXR&#x3b3;. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.

Selective RXR ligands

Growing community of inventors

Durham, NC, United States of America

Aaron Bayne Miller